Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMMX vs NBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMMX Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 3–4 Matrix Metrics)

IMMX Overall Winner 6-Pillar Tally: IMMX 4 – 1 NBP (1 Tie) Matrix Metrics: IMMX 3 – 4 NBP

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IMMX carries a Unified Composite Score of 48.6/100 (HOLD) at $7.58 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. IMMX 48.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMMX vs NBP
IMMX NASDAQ Head-to-Head Winner
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.58
-3.25% 1D
Market Cap $655.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 46.0 Fund 55.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $8.05 · SMA50: $9.69
NBP US Equity
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
TTM Revenue N/A
Forward P/E 2.7x
Beta / 30D Vol 1.66β · 81% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 20
RSI-14: 20.1 · SMA20: $1.08 · SMA50: $1.31

6-Pillar Scorecard Institutional Category Breakdown (IMMX 4 – 1 NBP)

Columns: Metric · IMMX · NBP
1. Valuation Multiples NBP
Forward P/E N/M 2.7x
Trailing P/E N/M 2.7x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale IMMX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $655.8M $96.3M
3. Profitability & Quality IMMX
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -27.0% -59.1%
4. Balance Sheet & Cash Flow IMMX
Cash Generation (TTM) -$39M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $224M Net Cash $1.73 Book/Sh · -59.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.6% (17th %ile) N/A (N/A)
Put/Call OI Skew 1.24x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMMX (3) vs NBP (4)
Institutional Metric IMMX NBP Criterion Row Edge
Market Capitalization
Scale
$655.8M $96.3M Larger Scale IMMX
Trailing P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Forward P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-27.0% -59.1% Higher ROE IMMX
52-Week Range Position
Momentum
36% ($3–$15) 0% ($1–$5) Stronger Trend IMMX
Beta / 30D Volatility
Risk Regime
1.80β · 84% Vol 1.66β · 81% Vol Lower Realized Risk NBP
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 51.9 / 100 (HOLD) Higher Composite NBP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$39M ($224M Net Cash) N/A ($1.73 Book/Sh · -59.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMMX +32.09 pp
IMMX: -4.95% · NBP: -37.04%
3M Horizon IMMX +22.26 pp
IMMX: -35.77% · NBP: -58.03%
6M Horizon IMMX +37.98 pp
IMMX: -15.63% · NBP: -53.61%
1Y Horizon IMMX +191.09 pp
IMMX: +110.11% · NBP: -80.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs NBP. Trailing 12-month operating profitability (IMMX 0.0% vs NBP 0.0%) and valuation multiples (IMMX N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M
NBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.1% · 2.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $655.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMMX vs NBP Key Questions & Quantitative Answers

As of Nov 16, 2026, Immix Biopharma, Inc. (IMMX) is the stronger overall head-to-head candidate over NBP (NBP) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IMMX carries a Unified Composite Score of 48.6/100 (HOLD) at $7.58 (N/M Forward P/E, 0.0% operating margin), whereas NBP carries 51.9/100 (HOLD) at $0.79 (2.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NBP currently prints a higher short-term Unified Composite Score (51.9/100 HOLD vs. IMMX 48.6/100 HOLD), IMMX captures the overall institutional head-to-head verdict (3–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMMX leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus N/A for NBP. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NBP.

NBP screens cheaper on headline valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus NBP (-59.1% ROE) capital efficiency.

In options market volatility and institutional positioning, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk). By comparison, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.